The article Atai Completes Enrollment of Phase 2a Trial for Depression was originally published on Microdose. atai Life Sciences has moved its most advanced...
The article A Deeper Look at Atai Life Sciences’ R&D Day was originally published on Microdose. Today, atai Life Sciences (Nasdaq: ATAI) held its...
October 24, 2022 Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced...
MindMed saw several management changes over the last nine months. The post MindMed Mess Results in Stock Price Roller Coaster appeared first on Green Market...
The article Top 5 Psychedelic Clinical Trials in 2022 was originally published on Microdose. In order for psychedelic medicines to be legalized in a doctor-prescribed...
Silo Pharma (NASDAQ: SILO) shares are catching a bid, moving 16% higher to reach $6.39 on Tuesday. The move isn’t surprising; SILO is attracting the...
MindMed ($MNMD) – the starry-eyed prospect in the psychedelic biotech space has recently turned into a soap opera starring Freeman Capital, angry retail...
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...
The article Breaking News: Compass Pathways to run TWO Phase 3 Trials for Depression was originally published on Microdose. Today, psychedelic medicine...
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety,...